It has been shown that HTATIP2/TIP30 levels are decreased in variant-small cell lung carcinoma (V-SCLC), classic-SCLC, neuroblastoma (NB), colon cancer, melanoma, prostate cancer, and hepatocellular carcinoma (HCC) [23–24]. This evidence concerns the gene HTATIP2 and melanoma.